VIDAS3® TB-IGRA assay: evaluation of performance characteristics in a predominantly low risk, low incidence population
Authors:
- 7 January 2023
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 105 (4) , 115885
Abstract
No abstract availableKeywords
Funding Information
- bioMérieux
This publication has 8 references indexed in Scilit:
- Latent Tuberculosis InfectionNew England Journal of Medicine, 2021
- Global Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets — Worldwide, 2018MMWR. Morbidity and Mortality Weekly Report, 2020
- Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020MMWR. Recommendations and Reports, 2020
- The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical ModellingPLOS Medicine, 2016
- Towards tuberculosis elimination: an action framework for low-incidence countriesEuropean Respiratory Journal, 2015
- Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysisClinical Rheumatology, 2014
- Is the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening?American Journal of Clinical Pathology, 2009
- THE PROGNOSIS OF A POSITIVE TUBERCULIN REACTION IN CHILDHOOD AND ADOLESCENCEAmerican Journal of Epidemiology, 1974